Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme.

Journal: BMC Pulmonary Medicine
Treatment Used: Oral Rifampicin and Fusidic Acid, Inhaled Vancomycin, and Nasal Mupirocin
Number of Patients: 7
MediFind Summary

Summary: This study tested the safety and efficacy of using a short-term local and systemic antibiotic scheme to treat patients with MRSA infections alongside cystic fibrosis.

Conclusion: The study found that 86% of patients achieved successful eradication of MRSA upon first treatment.


Background: In individuals with cystic fibrosis (CF), colonization with methicillin-resistant Staphylococcus aureus (MRSA) was reported to be associated with a deterioration of pulmonary disease as reflected by an accelerated decline in lung function. Thus, an early eradication of MRSA could be beneficial in these patients. Here, we report on an intensified MRSA eradication protocol.

Methods: Since 2012 a protocol for the eradication of newly acquired MRSA has been used in our CF Clinic, combining oral rifampicin and fusidic acid, inhaled vancomycin, nasal mupirocin, local antiseptic treatment and hygienic directives all of which are applied for only 7 days during an inpatient hospital stay.

Results: Since 2012 seven patients (3 male, 4 female; age range 4 to 30 years) newly acquired MRSA. In 6 of the 7 patients (86%) successful eradication of MRSA was achieved upon first treatment using the protocol described above. In one patient a second course of treatment was performed which, however, also failed to eliminate the colonizing MRSA.

Conclusions: Our protocol led to an eradication rate of 86%. The impact of each individual component of the protocol remains to be determined.

Similar Latest Advances